A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.

Garcia, J LLozano, RMisiewicz-Krzeminska, IFernandez-Mateos, JKrzeminski, PAlfonso, SMarcos, R AGarcia, RGomez-Veiga, FVirseda, AHerrero, MOlmos, DCruz-Hernandez, J J2023-01-252023-01-252017-06-09García JL, Lozano R, Misiewicz-Krzeminska I, Fernández-Mateos J, Krzeminski P, Alfonso S, et al. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. Clin Transl Oncol. 2017 Nov;19(11):1350-1357http://hdl.handle.net/10668/11290Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified. The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score ≥7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors.enAR-V7Androgen receptorCD133Capillary nano-immunoassayCirculating tumor cellsPTENAC133 AntigenAlternative SplicingBiomarkers, TumorFollow-Up StudiesHumansImmunoassayMaleNanomedicineNeoplastic Cells, CirculatingPilot ProjectsPrognosisProstatic NeoplasmsReceptors, AndrogenA novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.research article28600675Restricted accessInmunoensayoCapilaresPlasmaNeoplasias de la próstataReceptores androgénicosBiomarcadoresCastración10.1007/s12094-017-1675-51699-3055https://digital.csic.es/bitstream/10261/169283/4/anovelpatient.pdf